<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192711</url>
  </required_header>
  <id_info>
    <org_study_id>MTD003</org_study_id>
    <nct_id>NCT01192711</nct_id>
  </id_info>
  <brief_title>Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice</brief_title>
  <acronym>DID3</acronym>
  <official_title>An Open Label, Multicentre, Randomized Study of Insulin Glargine + Prandial Insulin Glulisine Associated With a Telemedicine System for Carbohydrates Counting vs. Insulin Glargine + Prandial Insulin Glulisine Associated With Common Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Consorzio Mario Negri Sud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>LifeScan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Consorzio Mario Negri Sud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Diabetes Interactive Diary (DID) is both a CHO (carbohydrates )/insulin bolus calculator,
      an information technology and a telemedicine system based on the communication between health
      care professional and patient by SMS messages.

      Aim of the study is to compare an insulin regimen of insulin glargine + prandial insulin
      glulisine associated with a telemedicine system to teach CHO counting (DID) with the same
      insulin regimen administered according to usual practice.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood levels of glycosylated hemoglobin</measure>
    <time_frame>from baseline every three months until the end of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood glucose (BG) levels</measure>
    <time_frame>from baseline every three months until the end of the study</time_frame>
    <description>Changes in BG levels from baseline to end of study (fasting BG, pre-/post-prandial BG, nocturnal BG, mean daily BG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability</measure>
    <time_frame>from baseline every three months until the end of the study</time_frame>
    <description>Glucose variability (MAGE, coefficient of variation of mean fasting BG and post-prandial BG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight and BMI</measure>
    <time_frame>from baseline every three months until the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily insulin dose, total basal insulin dose, total prandial insulin dose</measure>
    <time_frame>from baseline every three months until the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>at baseline and at the end of the study</time_frame>
    <description>the quality of life will be measured by Diabetes Specific Quality of Life Scale (DSQOLS) and Diabetes Treatment Satisfaction Questionnaire (DTSQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of patients with hypoglycemic episodes and frequency of hypoglycemic episodes overall</measure>
    <time_frame>every three months until the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of patients with severe and/or symptomatic hypoglycemia and frequency of severe and/or symptomatic hypoglycemic episodes overall</measure>
    <time_frame>every three months until the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and times of hypoglycemic events with regard to occurrence during the day (24 hours) and total treatment duration (24 weeks)</measure>
    <time_frame>every three months until the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>insulin + DID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three prandial (before or at the end of meal administration, based on doctor counselling and patient decision) injections per day of insulin glulisine associated with basal insulin glargine; the DID will be used to estimate the CHO content of the food intended to eat. Insulin doses in this group will be adjusted based on DID calculations and pre-meal BG values.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>insulin + usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Three prandial (before or at the end of meal administration, based on doctor counselling and patient decision) injections of insulin glulisine associated with basal insulin glargine. Insulin doses in group B will be adjusted based on SMBG values reviewed during the doctor office visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diabetes Interactive Diary (DID)</intervention_name>
    <description>DID is both a CHO/insulin bolus calculator, an information technology and a telemedicine system based on the communication between health care professional (physician or dietitian) and patient by SMS messages.</description>
    <arm_group_label>insulin + DID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with type 1 diabetes as defined by the criteria of the Expert Committee on
             the Diagnosis and Classification of Diabetes Mellitus (29)

          -  Males and females

          -  Age equal or more than 18 years

          -  Patients not habitually using CHO (carbohydrates) counting

          -  Self monitoring blood glucose (SMBG) at least 3 times a day

          -  Four basal-bolus daily injections of short-acting and long-acting insulin analogues

          -  HbA1c equal or more than 7.5%

          -  Female patients have to be postmenopausal, hysterectomised or surgically sterilized or
             using reliable and adequate contraceptive methods (oral contraception or IUD);

          -  A full study-specific informed consent must be obtained in writing for all subjects

        Exclusion Criteria:

          -  Multiple daily injections of NPH insulin or soluble rapid insulin or Continuous
             Subcutaneous Insulin Infusion (CSII) therapy

          -  Mental conditions, depression, or high anxiety rendering the subject unable to
             understand the nature, scope, and possible consequences of the study

          -  Eating disorders

          -  Pregnancy / lactation.

          -  Any clinically significant major organ system disease such as relevant cardiovascular,
             gastrointestinal, hepatic, neurological, endocrine, haematological or other major
             systemic diseases or infective diseases making implementation of the protocol or
             interpretation of the study results difficult

          -  Any disease or condition including abuse of illicit drugs, prescription medicines or
             alcohol that in the opinion of the investigator may interfere with the completion of
             the study

          -  Subjects unlikely to comply with protocol, e.g., uncooperative attitude, inability to
             return for follow-up visits, and unlikelihood of completing the study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Nicolucci, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Consorzio Mario Negri Sud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Nicolucci, MD</last_name>
    <phone>+39 0872 570</phone>
    <phone_ext>260</phone_ext>
    <email>nicolucci@negrisud.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria C Rossi</last_name>
    <phone>+39 0872 570</phone>
    <phone_ext>266</phone_ext>
    <email>mrossi@negrisud.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale G.B. Morgagni - L. Pierantoni</name>
      <address>
        <city>Forlì</city>
        <zip>47100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Acquati, MD</last_name>
      <phone>+39 0543 731199</phone>
      <email>s.acquati@ausl.fo.it</email>
    </contact>
    <investigator>
      <last_name>Silvia Acquati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>P.O. di Grosseto - Stabilimento Misericordia</name>
      <address>
        <city>Grosseto</city>
        <zip>58100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Rossi, MD</last_name>
      <phone>+39 0564 485272</phone>
      <email>m.rossi@usl9.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Mauro Rossi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az. Osp. S. Anna - Presidio Ospedaliero Cantù - Mariano Comense</name>
      <address>
        <city>Mariano Comense</city>
        <zip>22066</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Sciangula, MD</last_name>
      <phone>+39 031 755357</phone>
      <email>luigi.sciangula@hsacomo.org</email>
    </contact>
    <investigator>
      <last_name>Luigi Sciangula, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Laurenzi, MD</last_name>
      <phone>+39 02 2643</phone>
      <phone_ext>2894</phone_ext>
      <email>laurenzi.andrea@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Gabriella Galimberti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda Cà Granda</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea M Bonomo, MD</last_name>
      <phone>+39 02 64443912</phone>
      <email>matteo.bonomo@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Andrea M Bonomo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>II Università di Napoli Centro Regionale di Diabetologia Pediatrica &quot;G. Stoppoloni&quot;</name>
      <address>
        <city>Naples</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dario Iafusco, MD</last_name>
      <phone>+39 081 5665434</phone>
      <email>dario.iafusco@unina2.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Prisco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Padova Dipartimento di Medicina Clinica e Sperimentale</name>
      <address>
        <city>Padua</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Maran, MD</last_name>
      <phone>+39 049 8212097</phone>
      <email>alberto.maran@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Alberto Maran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Cisanello</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Del Prato, MD</last_name>
      <phone>+39 050 995100</phone>
      <email>delprato@immr.med.unipi.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Del Prato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Diabetologia, Dip. di Malattie Digestive &amp; Metaboliche</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Di Bartolo, MD</last_name>
      <phone>+39 0544 286326</phone>
      <email>p.dibartolo@ausl.ra.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Di Bartolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Infermi</name>
      <address>
        <city>Rimini</city>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cinzia Trojani, MD</last_name>
      <phone>+39 0541 705370</phone>
      <email>ctrojani@auslrn.net</email>
    </contact>
    <investigator>
      <last_name>Cinzia Trojani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Sandro Pertini</name>
      <address>
        <city>Rome</city>
        <zip>00157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Concetta Suraci, MD</last_name>
      <phone>+39 06 41433513</phone>
      <email>tsuraci@tiscali.it</email>
    </contact>
    <investigator>
      <last_name>Concetta Suraci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Magati</name>
      <address>
        <city>Scandiano</city>
        <zip>42019</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valerio Miselli, MD</last_name>
      <phone>+39 0522 850247</phone>
      <email>miselliv@ausl.re.it</email>
    </contact>
    <investigator>
      <last_name>Valerio Miselli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera-Universitaria S. Giovanni Battista</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgio Grassi, MD</last_name>
      <phone>+39 011 6335605</phone>
      <email>giorgio.grassi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giorgio Grassi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>August 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <last_update_submitted>September 1, 2010</last_update_submitted>
  <last_update_submitted_qc>September 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Antonio Nicolucci/Chair of the Steering Committee</name_title>
    <organization>Consorzio Mario Negri Sud</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>telemedicine</keyword>
  <keyword>self monitoring blood glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

